Literature DB >> 14767395

WCA recommendations for the long-term treatment of panic disorder.

Mark H Pollack1, Christer Allgulander, Borwin Bandelow, Giovanni B Cassano, John H Greist, Eric Hollander, David J Nutt, Ahmed Okasha, Richard P Swinson.   

Abstract

What are the symptoms of panic disorder and how is the disorder most effectively treated? One of the most commonly encountered anxiety disorders in the primary care setting, panic disorder is a chronic and debilitating illness. The core symptoms are recurrent panic attacks coupled with anticipatory anxiety and phobic avoidance, which together impair the patient's professional, social, and familial functioning. Patients with panic disorder have medically unexplained symptoms that lead to overutilization of healthcare services. Panic disorder is often comorbid with agoraphobia and major depression, and patients may be at increased risk of cardiovascular disease and, possibly, suicide. Research into the optimal treatment of this disorder has been undertaken in the past 2 decades, and numerous randomized, controlled trials have been published. Selective serotonin reuptake inhibitors have emerged as the most favorable treatment, as they have a beneficial side-effect profile, are relatively safe (even if taken in overdose), and do not produce physical dependency. High-potency benzodiazepines, reversible monoamine oxidase inhibitors, and tricyclic antidepressants have also shown antipanic efficacy. In addition, cognitive-behavioral therapy has demonstrated efficacy in the acute and long-term treatment of panic disorder. An integrated treatment approach that combines pharmacotherapy with cognitive-behavioral therapy may provide the best treatment. Long-term efficacy and ease of use are important considerations in treatment selection, as maintenance treatment is recommended for at least 12-24 months, and in some cases, indefinitely.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14767395     DOI: 10.1017/s109285290000691x

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  7 in total

Review 1.  Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia.

Authors:  T A Furukawa; N Watanabe; R Churchill
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Management of treatment-resistant panic disorder.

Authors:  Richard L Holt; R Bruce Lydiard
Journal:  Psychiatry (Edgmont)       Date:  2007-10

3.  A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

Authors:  Mark Pollack; Richard Mangano; Richard Entsuah; Evan Tzanis; Naomi M Simon; Ying Zhang
Journal:  Psychopharmacology (Berl)       Date:  2007-06-23       Impact factor: 4.530

4.  Cytokine profile in drug-naïve panic disorder patients.

Authors:  Laiana A Quagliato; Antonio E Nardi
Journal:  Transl Psychiatry       Date:  2022-02-22       Impact factor: 6.222

5.  Persistent depression and anxiety in the United States: prevalence and quality of care.

Authors:  Alexander S Young; Ruth Klap; Rebecca Shoai; Kenneth B Wells
Journal:  Psychiatr Serv       Date:  2008-12       Impact factor: 4.157

6.  Pharmacological management of panic disorder.

Authors:  Carlo Marchesi
Journal:  Neuropsychiatr Dis Treat       Date:  2008-02       Impact factor: 2.570

7.  A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study.

Authors:  James M Prosser; Samantha Yard; Annie Steele; Lisa J Cohen; Igor I Galynker
Journal:  BMC Psychiatry       Date:  2009-05-26       Impact factor: 3.630

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.